Cholesterol Update, and a Clarification


The Cholesterol Update:

     Back in August I posted an optimistic blog entitled, "Reading Between the Lines":

I wrote, enthusiastically, about getting to re-start a cholesterol lowering medication.  My targeted chemotherapy has been working long enough that I didn't want to forget about other health issues.  Who knows, maybe there's a possibility that I may live long enough to worry about cardiovascular consequences of untreated high cholesterol.  So, in August, I started on a low dose of atorvastatin, (generic Lipitor), with the idea that we'd monitor my lipids and liver enzymes and make any needed adjustments.  I was feeling pretty damn cocky that I got to start back on atorvastatin.  

     A couple weeks ago I had follow-up blood tests to check my lipid profile and liver enzymes.  Great news!  My lipid profile was completely normal.  My cholesterol value, (which is usually in the mid-200's when on medication and in the 300's when off of medication,) was 162.  But, my liver enzymes were abnormally high.  Crap.  My cholesterol was low because I was knocking out my liver.  So...I'm off atorvastatin.  Crap...again.


and The Clarification:

     My last post had some information that I had misunderstood.  Thank you to my fellow ROS1 cancer ninja friends, Tori and Janet, for correcting my understanding about our medication, Xalkori.  

     Xalkori has not yet been FDA fast-tracked nor approved for ROS1-positive lung cancer.  It is still in clinical trials and is being used "off label" for ROS1 patients based on the available data for a similar mutation called ALK.  The recent New England Journal of Medicine's article presented data for its use with ROS1-positive patients, which is a step toward getting Xalkori approved by the FDA for ROS1-positive lung cancer.  This is really an important article.  With this data, insurance companies will have more trouble denying coverage for it. 

     

 

Comments

Popular posts from this blog

Port Details

CT Scans #4, Update

Because Stage 4 Cancer Isn't Enough-Part 3